Alpha Cognition (ACOG) Expected to Release Quarterly Earnings on Wednesday

Alpha Cognition (NASDAQ:ACOG) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Alpha Cognition to post earnings of ($0.33) per share and revenue of $7.04 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.01). The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative net margin of 153.61% and a negative return on equity of 54.60%. On average, analysts expect Alpha Cognition to post ($1.38) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $8.29 on Monday. The stock has a market cap of $180.56 million, a P/E ratio of -7.54 and a beta of 2.32. Alpha Cognition has a 1-year low of $4.50 and a 1-year high of $10.14. The firm has a 50-day moving average of $8.80 and a two-hundred day moving average of $7.21.

Insider Activity at Alpha Cognition

In related news, Director Robert Wills bought 10,000 shares of the stock in a transaction dated Friday, August 21st. The stock was bought at an average cost of $9.62 per share, with a total value of $96,200.00. Following the completion of the acquisition, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ACOG. Craig Hallum reiterated a “buy” rating and set a $17.00 target price on shares of Alpha Cognition in a research note on Friday, August 14th. B. Riley Financial began coverage on shares of Alpha Cognition in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price objective for the company. Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright boosted their target price on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Five analysts have rated the stock with a Buy rating. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $18.00.

About Alpha Cognition

Alpha Cognition Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition.

Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type.